# IMRX — Immuneering Corp · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** IMRX  
**Sources:** 20  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-imrx-immuneering-corp-catalysts-narrative-risks-10410

---

## Context (as of 2026-10-31)

Immuneering Corporation (Nasdaq: IMRX) is a late-stage clinical oncology company headquartered in Cambridge, Massachusetts, developing atebimetinib (IMM-1-104), an oral MEK/RAF inhibitor in a pivotal Phase 3 trial for pancreatic cancer, plus a lung-cancer combination program and discovery-stage programs [[1]](https://www.marketscreener.com/news/immuneering-reports-third-quarter-2026-financial-results-and-provides-business-updates-ce785fdadd81f127), [[7]](https://www.stockwatch.com/News/Item/U-z9856352-U!IMRX-20261029/U/IMRX), [[16]](https://stockanalysis.com/stocks/imrx/). As of late October the stock traded around $3.74, roughly 56% below its 52-week high of $8.48 [[16]](https://stockanalysis.com/stocks/imrx/), [[17]](https://www.marketbeat.com/stocks/NASDAQ/IMRX/).

## Key Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-imrx-immuneering-corp-catalysts-narrative-risks-10410 (free to sign up)._